典型文献
Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting
文献摘要：
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma (NHL) and has high heterogene-ity. Approximately 30％–50％ of patients develop relapsed/refractory (R/R) disease, which remains a major cause of mortality1-3. In recent years, a variety of novel therapies have emerged, including bispecific T-cell engagers (BiTEs), anti-body–drug conjugates (ADCs), chimeric antigen receptor T cells (CAR-T), and selective BTK inhibitors, which have pro-vided effective treatment strategies for patients with DLBCL1,4. Recently, the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, presenting cutting-edge studies in DLBCL. Here, we discuss a selection of interesting data on this topic.
文献关键词：
中图分类号：
作者姓名：
Minghan Qiu;Shan Wu;Xinrui Chen;Huaqing Wang
作者机构：
Department of Oncology,Tianjin Union Medical Center,Nankai University,Tianjin 300191,China;The Institute of Translational Medicine,Tianjin Union Medical Center,Nankai University,Tianjin 300121,China
文献出处：
引用格式：
[1]Minghan Qiu;Shan Wu;Xinrui Chen;Huaqing Wang-.Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting)[J].癌症生物学与医学（英文版）,2022(08):1117-1120
A类：
mortality1,engagers,BiTEs,DLBCL1,58th
B类：
Update,diffuse,large,lymphoma,highlights,from,ASCO,Annual,Meeting,Diffuse,most,common,Hodgkin,NHL,has,heterogene,Approximately,patients,develop,relapsed,refractory,disease,which,remains,major,cause,In,recent,years,variety,novel,therapies,have,emerged,including,bispecific,body,drug,conjugates,ADCs,chimeric,antigen,receptor,cells,CAR,selective,BTK,inhibitors,vided,effective,treatment,strategies,Recently,American,Society,Clinical,Oncology,was,held,Chicago,presenting,cutting,edge,studies,Here,we,discuss,selection,interesting,data,this,topic
AB值：
0.676252
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
